To compare laparoscopic versus ultrasound puncture sclerotherapy for treatment of ovarian endometriosis cysts in young women: a single-center, randomized, controlled study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044150

Enrollment

Unknown

Registered

2021-03-11

Start date

2021-03-22

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian endometrioma

Interventions

The group of laparoscopic surgery:Laparoscopic surgery

The group pf Ultrasonic puncture sclerotherapy:Ultrasonic puncture sclerotherapy

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. The applicant is 18-35 years old and has no need to give birth within 1 year. 2. The ovarian reserve function is normal (Standard of normal ovarian reserve function: AFC (5-6 ovaries/each side; AMH > 2.0 ng/ml). 3. B-ultrasound (transrectal/vaginal color ultrasound, ultrasound angiography of cyst wall) and clinical examination (gynecologic examination, tumor markers) were considered as unilateral single OEM, 4cm <= cyst diameter <= 8cm. 4. All patients received treatment in this study within 3-7 days after menstruation was clean. 5. The vaginal secretions of persons with sexual life are required to be within II degrees of cleanliness

Exclusion criteria

Exclusion criteria: 1. Abnormal increase of tumor marker CA-125 over 500IU/L; Alternatively, ultrasound angiography may indicate that there is abundant blood flow in the cyst or cyst wall, and MRI plain scan + enhancement is needed to exclude malignancy. 2. Postoperative pathology indicated borderline or malignant or non-OEM benign tumor. 3. Chronic diseases of heart, liver, brain, lung and other organs cannot tolerate laparoscopic surgery. 4. Previous ovarian surgery, one-ovary and/or salpingectomy or hysterectomy due to OEM or other ovarian diseases 5. There are contraindications to the use of progesterone, such as thromboembolic disease, breast cancer, meningioma, etc. 6. Can not adhere to the medication or can not cooperate with the follow-up. 7. There is a serious bleeding tendency, abnormal coagulation mechanism or taking anticoagulants. 8. In the ultrasound intervention group, the increase of OEM or suspected malignant changes during follow-up required surgical intervention.

Design outcomes

Primary

Measure	Time frame
The recurrence rate of OEM;	—

Secondary

Measure	Time frame
Ovarian reserve function;	—

Countries

China

Contacts

Public ContactWeixia Wei

Peking University Shenzhen Hospital

weixwei_2013@126.com+86 13688809932

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026